Natco extends scope of agreement with US-based Akorn

New Delhi, Nov 3 (UNI) Hyderabad's Natco Pharma Ltd has added two injectable drugs to its existing API Supply and Margin Sharing Agreement with United States-based Akorn.

With this agreement, the total number of products covered under the agreement goes up to four.

The two drug products are indicated for the prevention of nausea and vomiting associated with cancer chemotherapy, and have a combined current market size of approximately 360 million dollars.

Under the API Supply and Margin Sharing Agreement that was signed in April this year, the company will be responsible for the supply of active pharmaceutical ingredients for both drug products, while Akorn will be responsible for the manufacturing, regulatory submissions, marketing and distribution in the hospital, clinic, and home healthcare markets in the US and Canada.

UNI PKS DKS VV1733